期刊文献+

使用标准化服务包对耐多药肺结核患者住院费用的影响 被引量:2

Analysis on the hospitalization expense of multi-drug resistant tuberculosis patients treated in standard package
暂未订购
导出
摘要 目的:分析使用标准化服务包治疗对耐多药肺结核患者住院费用的影响。方法:通过结构式调查表收集项目干预期间107例耐多药肺结核患者的基本情况和住院信息,采用广义线性模型进行多因素分析。结果:使用标准服务包治疗的耐多药肺结核患者次均住院费用为3819.49元,日均住院费用为97.84元,分别为未使用标准服务包治疗患者的52.51%和44.23%;患者住院药品费用所占比例由59.93%下降到26.59%,但辅助检查费由8.44%上升到25.62%。干预后患者的登记分类、定点医院床位数和住院天数对患者住院费用影响有统计学意义。结论:标准服务包能够控制耐多药肺结核患者住院费用,使患者得到规范治疗并有助于提高治疗的质量,在耐多药肺结核诊治过程中有必要推广使用标准服务包。 Objective: To analyze the hospitalization expense of muhi-drug resistant tuberculosis patients treated in standard package and the influence factors of the hospitalization expense. Methods : The basic information and hos- pitalization of 107 MDR-TB patients who treated in standard package were collected using structure questionnaires. The generalized linear model would be used to analyze the influence factors. Results: The hospitalization expense af- ter using the standard service package were 3 819.49 Yuan/time and 97.84 Yuan/day/time, account for 52.51% and 44.23% of the hospitalization expense before the intervention. The drug component declined from 59.93% to 26.59% ,at the same time, the examinations component increased from 8.44% to 25.62% . The register type, hos- pital beds and hospital days were the influence factors. Conclusions: The standard package could reduce the hospital- ization expense of MDR-TB patients. Patients could be treated according to recommended standards. Promoting the use of standard service package is necessary.
出处 《中国卫生政策研究》 CSCD 2013年第4期66-70,共5页 Chinese Journal of Health Policy
基金 中盖结核病项目医防合作子项目评估(2011CCDC)
关键词 耐多药肺结核 住院费用 标准化服务包 Multi-drug resistant tuberculosis Hospitalization expense Standard service package
  • 相关文献

参考文献11

  • 1Towards universal access to diagnosis and treatment of multi- drug-resistant and extensively drug-resistant tuberculosis by 2015[R].
  • 2Multidrug and extensively drug-resistant TB (M/XDR-TB) : 2010 global report on surveillance and response[ R]. WHO, 2010.
  • 3Ahmad S, Mohandas E. Recent advances in the diagnosis and treatment of muhidrug-resistant tuberculosis [ J ]. Re- spiratory Medicine, 2009, 103(12): 1777-1790.
  • 4程晓明.卫生经济学[M].北京:人民卫生出版社,2007.38-63.
  • 5Suerez P G, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru [J]. Lancet, 2002, 359(9322): 1980-1989.
  • 6Eker B, Ortmann J, Migliori G B, et al. Muhidrug-and ex- tensively drug-resistant tuberculosis, Germany [J]. Emer- ging Infectious Diseases, 2008, 14(11 ): 1700-1706.
  • 7孙强,闫赟,边学峰,张加胜,李文婧,陈诚,赵津,李仁中.耐多药肺结核患者医疗费用及经济负担分析[J].中国卫生经济,2011,30(1):33-35. 被引量:30
  • 8Rouzier V A, Oxlade O, Verduga R, et al. Patient and fam- ily costs associated with tuberculosis, including muhidrug- resistant tuberculosis, in Ecuador [ J ]. Int J Tuberc Lung Dis, 2010, 14(10) : 1316-1322.
  • 9Post F A, Willcox P A, Mathema B, et al. Genetic poly- morphism in Mycobacterium tuberculosis isolates from pa- tients with chronic muhidrug-resistant tuberculosis [ J ]. J Infect Dis, 2004, 190(1 ) : 99-106.
  • 10Gandhi N R, Nunn p, Dheda K, et al. Muhidrug-resistant and extensively drug-resistant tuberculosis : a threat to glob- al control of tuberculosis [J]. Lancet, 2010, 375(9728) : 1830-1843.

二级参考文献7

  • 1李亮,傅瑜.耐药结核病的现状与展望[J].结核病健康教育,2008(1):17-20. 被引量:3
  • 2WorldHealth Organization Stop TB Department.耐药结核病规划管理指南2008年紧急修订版[EB/OL].[2008-09-07].http://whqlibdoc.who.int/publications/2008/978924154758l_chi.pdf.
  • 3World Health Organization. Global tuberculosis control : Epidemiology, strategy, financing[R]: WHO report 2009. WHO/HTM/ TB/2009.
  • 4耐多药结核高负担国家部长级会议.解决预防耐多药,广泛耐药结核病与加强控制并扩大患者治疗的关键瓶颈问题[EB/OL].[2009-08-10].http://www.who.int/tb/tlenecks-full-v-ersion_zh.pdf.
  • 5Kawabata K, Xu K, Can-in C. Prevent impoverishment through protection against catastrophic health expenditure[J].Geneva.Bulletion of the world health organization, 2002(8) : 80.
  • 6Suarez AG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of Standardized second line drug treatment for chronic tuberculosis patients: a national cohort study in Peru[J]. The Lancet. 2002(359): 181-190.
  • 7方豪,赵郁馨,王建生,万泉,杜乐勋.卫生筹资公平性研究——家庭灾难性卫生支出分析[J].中国卫生经济,2003,22(6):5-7. 被引量:50

共引文献74

同被引文献20

引证文献2

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部